Comparative Pharmacology
Head-to-head clinical analysis: QUADRAMET versus SODIUM FLUORIDE F 18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUADRAMET versus SODIUM FLUORIDE F 18.
QUADRAMET vs SODIUM FLUORIDE F-18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
None Documented
None Documented
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical